The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition

There is a need for antidepressants with novel mechanisms of action. One approach has been to develop compounds that inhibit reuptake of all three monoamines in the central nervous system, for example DOV216,303. Differential reinforcement of low-rate (72-s) responding is a behavioral test that is predictive of antidepressant-like properties. The effects of antidepressant compounds belonging to multiple classes, the anxiolytic diazepam and the antipsychotic haloperidol, were assessed in the DRL-72s task. Subsequently, the antidepressant-like properties of acute DOV216,303 were assessed. The selective serotonin reuptake inhibitor fluvoxamine, the preferential norepinephrine reuptake inhibitor desipramine and the tricyclic antidepressant imipramine exhibited antidepressant-like properties in the DRL-72s task. The atypical antidepressant bupropion, which inhibits dopamine and norepinephrine reuptake, and the selective dopamine transporter inhibitor GBR12909, changed reinforcement and response rates and inter-response time distribution in an opposite direction compared with the antidepressant compounds tested. The antipsychotic haloperidol exhibited antidepressant-like properties by increasing reinforcement rate, but failed to alter inter-response time distribution. Diazepam did not change reinforcement or response rates or inter-response time distribution. The triple reuptake inhibitor DOV216,303 significantly enhanced reinforcement rate at one intermediate dose, but exhibited similar effects as bupropion and GBR12909 on inter-response time distribution. The studies identified limited antidepressant-like properties of the triple reuptake inhibitor DOV216,303, likely due to dopamine transporter inhibition counteracting the effects of norepinephrine and serotonin transporter inhibition.

[1]  B. Haight,et al.  A Double-blind Comparison Between Bupropion XL and Venlafaxine XR: Sexual Functioning, Antidepressant Efficacy, and Tolerability , 2006, Journal of clinical psychopharmacology.

[2]  D. Luckenbaugh,et al.  Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. , 2008, The Journal of clinical psychiatry.

[3]  J. Richards,et al.  Sensitization to amphetamine on the differential-reinforcement-of-low-rate 72-s schedule , 1997, Psychopharmacology.

[4]  Susan G. Amara,et al.  Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor , 2000, Biological Psychiatry.

[5]  J. Richards,et al.  A quantitative interresponse-time analysis of DRL performance differentiates similar effects of the antidepressant desipramine and the novel anxiolytic gepirone. , 1991, Journal of the experimental analysis of behavior.

[6]  J. Richards,et al.  DRL interresponse-time distributions: quantification by peak deviation analysis. , 1993, Journal of the experimental analysis of behavior.

[7]  S. Fowler,et al.  Timing and space usage are disrupted by amphetamine in rats maintained on DRL 24-s and DRL 72-s schedules of reinforcement , 2009, Psychopharmacology.

[8]  J. O'Donnell,et al.  Postsynaptic α-2 Adrenergic Receptors are Critical for the Antidepressant-Like Effects of Desipramine on Behavior , 2009, Neuropsychopharmacology.

[9]  G. Marek,et al.  Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior , 2004, Psychopharmacology.

[10]  P. H. Andersen The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action , 1989 .

[11]  L. Seiden,et al.  Effects of monoamine oxidase inhibitors on performance during differential reinforcement of low response rate , 2004, Psychopharmacology.

[12]  R. Rosen,et al.  Effects of SSRIs on sexual function: a critical review. , 1999, Journal of clinical psychopharmacology.

[13]  R. Oosting,et al.  The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects , 2008, European Neuropsychopharmacology.

[14]  P. Czobor,et al.  Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. , 2006, CNS drug reviews.

[15]  G. Hertting,et al.  FLUVOXAMINE, A SPECIFIC 5‐HYDROXYTRYPTAMINE UPTAKE INHIBITOR , 1977, British journal of pharmacology.

[16]  G. Marek,et al.  Buspirone, gepirone, ipsapirone, and zalospirone have distinct effects on the differential-reinforcement-of-low-rate 72-s schedule when compared with 5-HTP and diazepam , 1994, Psychopharmacology.

[17]  L. Seiden,et al.  Differential effects of imipramine in rats as a function of DRL schedule value , 1980, Pharmacology Biochemistry and Behavior.

[18]  B. Olivier,et al.  Flesinoxan shows antidepressant activity in a DRL 72-s screen , 2005, Psychopharmacology.

[19]  G. Koob,et al.  Effects of corticotropin releasing factor, desipramine and haloperidol on a DRL schedule of reinforcement , 1989, Pharmacology Biochemistry and Behavior.

[20]  K. Chergui,et al.  Uptake of Dopamine Released by Impulse Flow in the Rat Mesolimbic and Striatal Systems In Vivo , 1995, Journal of neurochemistry.

[21]  J. L. Howard,et al.  Effects of imipramine, bupropion, chlorpromazine, and clozapine on differential‐reinforcement‐of‐low‐rate (DRL) > 72‐Sec and > 36‐sec schedules in rat , 1984 .

[22]  L. Seiden,et al.  Behavioral screen for antidepressants: The effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule , 2004, Psychopharmacology.

[23]  J. L. Howard,et al.  Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time greater than 72-s schedule. , 1986, Psychopharmacology.

[24]  Division on Earth Guide for the Care and Use of Laboratory Animals , 1996 .

[25]  K. E. Moore,et al.  Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons , 1986, Pharmacology Biochemistry and Behavior.

[26]  J. L. Howard,et al.  Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time >72-s schedule , 2004, Psychopharmacology.

[27]  H. Möller,et al.  Comparative Efficacy of Antidepressants , 2012, Drugs.

[28]  B. Lebowitz,et al.  Medication augmentation after the failure of SSRIs for depression. , 2006, The New England journal of medicine.

[29]  A. Janowsky,et al.  "Broad spectrum" antidepressants: is more better for the treatment of depression? , 2003, Life sciences.

[30]  M. Millan,et al.  Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors , 2002, Psychopharmacology.

[31]  G. Wenger,et al.  Behavioral effects of cocaine and its interaction with d-amphetamine and morphine in rats , 1990, Pharmacology Biochemistry and Behavior.

[32]  L. Seiden,et al.  BIMT 17: a putative antidepressant with a fast onset of action? , 1997, Psychopharmacology.

[33]  G. Marek,et al.  The 5-Hydroxytryptamine2A Receptor Antagonist R-(+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) Attenuates Impulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rate 72-s Behavior , 2008, Journal of Pharmacology and Experimental Therapeutics.

[34]  S. Stahl,et al.  SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants , 2005, CNS Spectrums.

[35]  A. Janowsky,et al.  Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. , 2003, European journal of pharmacology.

[36]  A. Schatzberg,et al.  A Prospective Trial of Bupropion SR Augmentation of Partial and Non-Responders to Serotonergic Antidepressants , 2003, Journal of clinical psychopharmacology.

[37]  J. D. Sokolowski,et al.  The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat , 1999, Psychopharmacology.

[38]  E. Richelson,et al.  Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. , 1984, European journal of pharmacology.

[39]  J. Amsterdam,et al.  Treatment resistant depression: methodological overview and operational criteria , 1999, European Neuropsychopharmacology.

[40]  R. Depoortère,et al.  Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat , 2006, Neuropsychopharmacology.

[41]  G. Marek,et al.  Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule , 2005, Neuroscience & Biobehavioral Reviews.

[42]  J. Feighner,et al.  Bupropion: a review of its mechanism of antidepressant activity. , 1995, The Journal of clinical psychiatry.

[43]  G. Marek,et al.  Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior. , 1989, The Journal of pharmacology and experimental therapeutics.

[44]  J. Modell,et al.  Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline , 1997, Clinical pharmacology and therapeutics.